Targeting mTOR Shows Promise in Cutaneous Sarcoidosis

Vienna researchers reported that 7 of 10 patients treated with systemic sirolimus had noted improvements in skin lesions, which continued for up to 2 years of follow-up.

Related Keywords

Vienna ,Wien ,Austria ,New York ,United States ,Austrian ,Georg Stary ,University Of Vienna ,Research Center ,Sarcoidosis Program ,Medical University ,Molecular Medicine ,Austrian Academy ,Vienna General ,Cutaneous Sarcoidosis Activity ,Morphology Index ,New York City ,Medscape Medical ,Sarcoidosis ,Arcoid ,Esnier Boeck Disease ,Clinical Research ,Clinical Trials ,Linical Studies ,Pre Clinical Trial ,Double Blind Study ,Double Blind Studies ,Ingle Blind Study ,Ingle Blind Studies ,Skin Lesion ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Healthcare Technology ,Medical Technology ,Biopsy ,Drug Withdrawal ,Eczema ,